Advanced Cell Technology

Advanced Cell Technology

Advanced Cell Technology is the previous name of Octa Therapeutics, which is now called Astellas Institute for Regenerative Medicine. The biotechnology company is a subsidiary of Astellas Pharma and was initially focused on the development of regenerative opthalmology therapeutics using stem cells.

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE.

In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

In 2014, Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

Timeline

People

Name
Role
LinkedIn

Adel Bakhtiarova

Employee

David Levy

Employee

David Levy

Investor

Jeffrey Long

Employee

Further reading

Title
Author
Link
Type
Date

Advanced Cell Technology Changes Name to Ocata Therapeutics

BusinessWire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.